9 Newly Approved Novel Drugs
It's been a busy year for the FDA.
3. Emflaza (deflazacort), Marathon Pharmaceuticals
Indication: A corticosteroid approved for treatment of Duchenne muscular dystrophy, the most common form of muscular dystrophy, in patients five years of age or older.
Dosage: Oral dosage approximately 0.9 mg/kg/day once daily; for oral suspension round up to the nearest tenth of a milliliter.
Contraindications: Known hypersensitivity to deflazacort or to any inactive ingredients.